Abiopharma

🔍 LEIDEN JEFFREY M (Executive)

Company: Odyssey Therapeutics, Inc. (ODTX)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $20.0 per share (Direct)
  Date: 2026-05-08 | Code: P | equity_swap_involved: false | shares_owned_after: 270,198.00 | transaction_form_type: 4
• Acquired 28,698 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | shares_owned_after: 28,698.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 2,963 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | shares_owned_after: 31,661.00 | transaction_form_type: 4 | Footnotes: F5, F4
• Sold 17 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-11 | Code: F | equity_swap_involved: false | shares_owned_after: 31,644.00 | transaction_form_type: 4 | Footnotes: F5, F6, F4
• Sold 8,527 shares of Series B Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F7, F4
• Sold 10,291 shares of Series C Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2, F7, F4
• Sold 9,880 shares of Series D Convertible Preferred Stock (Derivative)
  Date: 2026-05-11 | Code: C | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F7, F4
• Acquired 626,220 shares of Stock Option (Right to Buy) at $18.0 per share (Derivative)
  Date: 2026-05-07 | Code: A | Expires: 2036-05-06 | equity_swap_involved: false | shares_owned_after: 626,220.00 | transaction_form_type: 4 | Footnotes: F8
• Sold 2,963 shares of Series D Warrants (Right to Buy) at $0.1 per share (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F5, F5, F5, F4

Footnotes:

• F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
• F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
• F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
• F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
• F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.
• F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
• F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.